As part of this program, Chemizon’s scientists will develop and optimize new synthetic routes that are designed to reduce CG’s overall manufacturing costs and accelerate their development timelines.
“As CrystalGenomics continues its rapid growth, we regularly seek to identify reliable partners whose core competencies augment our internal capabilities. We were impressed by Chemizon’s process chemistry team and their technical capabilities. In addition, Chemizon’s proposal provided the best combination of scientific merit and financial creativity. We look forward to a successful partnership,” said Seonggu Ro, Ph.D., Vice President and CTO of CrystalGenomics.
“We are very pleased that CrystalGenomics chose Chemizon to execute this research program. Chemizon has assembled an outstanding scientific team and continues to build a world-class research organization with expertise in drug discovery and process research. This agreement with a top-tier life science company like CrystalGenomics, validates our efforts,” said Anthony Piscopio, Ph.D., Chairman and CEO of Chemizon Inc.